|
Females/Males [n]
|
18/22
|
|
Age [y, range]
|
3–18
|
|
[y, mean ± SD]
|
15.1 ± 4.7
|
|
Indications for EUS [n (%)]
|
|
Upper-GI EUS
|
32 (68.1)
|
|
• Suspected CBDs
|
8
|
|
• Acute biliary pancreatitis
|
7
|
|
• Recurrent/chronic pancreatitis
|
4
|
|
• Suspected CBDs in patients with UC
|
3
|
|
• Cystic pancreatic mass
|
3
|
|
• Recurrent hypoglycemia
|
2
|
|
• Duodenal polyp
|
2
|
|
• Pseudocyst drainage
|
1
|
|
• Gastric submucosal lesion
|
1
|
|
• Perigastric abscess
|
1
|
|
Lower-GI EUS
|
15 (31.9)
|
|
• Suspected anal Crohn’s Disease
|
12
|
|
• Fecal incontinence
|
2
|
|
• Encopresis
|
1
|
|
EUS-FNA [n (%)]
|
3 (6.4)
|
|
EUS procedures with sedation [n (%)]
|
| ○Upper GI |
|
• Deep sedation
|
22 (46.8)
|
|
• General anesthesia
|
10 (21.3)
|
| ○Lower GI |
|
• No sedation
|
14 (29.8)
|
|
• Deep sedation
|
1 (2.1)
|
|
Anesthesia-related adverse events [n (%)]
|
0
|
|
Clinical Impact of EUS [n (%)]
|
|
• Score 0
|
6 (12.8)
|
|
• Score 1
|
24 (51)
|
|
• Score 2
|
17 (36.2)
|
|
Significant impact (score 1 + 2)
|
41 (87.2)
|
